Skip to main content Skip to secondary navigation
Main content start

Jack Silberstein

Despite significant advances in screening and treatment, cancer remains a leading cause of death in the United States. Novel treatment approaches focus on boosting a person’s natural immunity to cancer, which can lead to durable responses due to patients being “vaccinated” against their specific cancer. Known as cancer immunotherapy, this approach works by blocking cancer’s ability to suppress recognition by the immune system. Though promising, certain challenges with cancer immunotherapy remain. My research applies innovative protein engineering methods to cancer immunotherapy to create more potent therapeutics with fewer off-target side effects. By using this approach, I am working to more effectively block cancer’s immunosuppression, thereby maximizing the therapeutic potential of cancer immunotherapy.